Substituted

1. A method of treating Alzheimer's disease in a patient in need, the method comprising administering to the patient a composition comprising a therapeutically effective amount of at least one compound selected from the group consisting of (E)-4-Ethoxystilbene (4k), (E)-4-N,N-Dimethylaminostilbene (4cc), (E)-3,4′-Dimethoxystilbene (6r), (E)-4′-Methoxy-3-methylstilbene (6i), (E)-2-Fluoro-4′-methoxystilbene (6p), (E)-3-Fluoro-4′-methoxystilbene (6n), (E)-4-Fluoro-4′-methoxystilbene (6m), (E)-3-Chloro-4′-methoxystilbene (6h) and (E)-4′-Methoxy-4-methylstilbene (6d), or a pharmaceutically acceptable salt, hydrate or solvate thereof, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

2. The method according to claim 1 wherein said compound inhibits NF-κB activity.

3. The method according to claim 1 wherein the compound inhibits AP-1 activity.

4. The method according to claim 1 wherein the compound inhibits NF-κB activity and AP-1 activity.

5. The method according to claim 1 wherein said at least one compound is selected from the group consisting of (E)-4-Ethoxystilbene (4k), (E)-4-N,N-Dimethylaminostilbene (4cc), (E)-3,4′-Dimethoxystilbene (6r), (E)-4′-Methoxy-3-methylstilbene (6i), (E)-2-Fluoro- 4 ′-methoxystilbene (6p), and (E)-4-Fluoro-4′-methoxystilbene (6m), or a pharmaceutically acceptable salt, hydrate or solvate thereof.

6. The method according to claim 1 wherein said at least one compound is selected from the group consisting of (E)-4-Ethoxystilbene (4k), (E)-4-N,N-Dimethylaminostilbene (4cc), (E)-3,4′-Dimethoxystilbene (6r), (E)-3-Fluoro-4′-methoxystilbene (6n) and (E)-2-Fluoro-4′-methoxystilbene (6p), or a pharmaceutically acceptable salt, hydrate or solvate thereof.

7. The method according to claim 1 wherein said at least one compound is selected from the group consisting of (E)-4-Ethoxystilbene (4k), (E)-4-N,N-Dimethylaminostilbene (4cc), (E)-3,4′-Dimethoxystilbene (6r) and (E)-2-Fluoro-4′-methoxystilbene (6p), or a pharmaceutically acceptable salt, hydrate or solvate thereof.

8. The method according to claim 1 wherein said at least one compound is selected form the group consisting of (E)-4-Ethoxystilbene (4k) and (E)-2-Fluoro-4′-methoxystilbene (6p), or a pharmaceutically acceptable salt, hydrate or solvate thereof.

9. The method according to claim 1 wherein said at least one compound is selected from the group consisting of (E)-4-N,N-Dimethylaminostilbene (4cc), (E)-3,4′-Dimethoxystilbene (6r), and (E)-2-Fluoro-4′-methoxystilbene (6p), or a pharmaceutically acceptable salt, hydrate or solvate thereof.

10. The method according to claim 1 wherein said at least one compound is selected from the group consisting of (E)-4-Ethoxystilbene (4k), (E)-4-N,N-Dimethylaminostilbene (4cc), (E)-3-Fluoro-4′-methoxystilbene (6n) and (E)-2-Fluoro-4′-methoxystilbene (6p), or a pharmaceutically acceptable salt, hydrate or solvate thereof.

11. The method according to claim 1 wherein said at least one compound is (E)-2-Fluoro-4′-methoxystilbene (6p) or a pharmaceutically acceptable salt, hydrate or solvate thereof.

12. The method according to claim 1 wherein said compound is administered by oral delivery.

13. The method according to claim 1 wherein said compound is administered by topical delivery.

14. A method of treating Alzheimer's disease in a patient in need, the method comprising administering to the patient a composition comprising a therapeutically effective amount of (E)-2-Fluoro-4′-methoxystilbene (6p), or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

15. The method according to claim 14 wherein said compound is administered by oral delivery.

16. The method according to claim 14 wherein said compound is administered by topical delivery.